MetaCap

Phibro Animal Health Corporation Class A (PAHC)

NASDAQ: PAHCHealth CareBiotechnology: Pharmaceutical PreparationsUSD

33.29-0.79 (-2.32%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PAHC stock chart

Technical analysis

Key statistics

All statistics
Dividend yield
1.44% ($0.48)
Ex-dividend date
Nov 25, 2026
52-week range
28.25 – 60.08
Day range
33.27 – 34.54
Volume / Avg
155.54K / 228.99K
Beta
—

52-week range

$28.25$60.08

PAHC stock today

Shares of Phibro Animal Health (PAHC) finished lower on Nov 20 at $33.29, a drop of 2.32% or $0.79 per share, versus the S&P 500's 3.70% decline. At this level, PAHC sits near the bottom of its 52-week range of $28.25 to $60.08: 44.6% below the high, set on Apr 13, 2026 and 17.8% above the low. PAHC is down 10.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 20.0%.

Phibro Animal Health trades at 13.3x its trailing twelve-month earnings per share of $2.51. Its forward P/E of 8.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. To receive the next $0.12 dividend, investors must own shares before the Nov 25 ex-dividend date.

Summary generated from market data by MetaCap's automated system. Methodology

About Phibro Animal Health

Company profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Daniel M. Bendheim J.D.
Headquarters
Teaneck, NJ
Employees
2,605
IPO year
2014
Website
pahc.com

Financial highlights

Full financials

In fiscal 2026, Phibro Animal Health generated $1.52 billion in revenue, up 17.1% from fiscal 2025, its 6th consecutive year of revenue growth. Net income was $99.7 million (+106.6% year over year), for a net margin of 6.6% versus a median of 3.7% in the prior 5 years. Gross margin was 33.8% (up from 30.9%) and operating margin 12.8%.

Phibro Animal Health annual revenue, net income and EPS
Fiscal yearFY 2026FY 2025FY 2024FY 2023FY 2022
Revenue$1.52B$1.30B$1.02B$977.89M$942.26M
Growth+17.12%+27.37%+4.07%+3.78%+13.07%
Net income$99.72M$48.26M$2.42M$32.61M$49.17M
EPS (diluted)$2.43$1.19$0.06$0.81$1.21

Analyst forecast

Forecast

Consensus (3 analysts)

hold

Avg. price target

$47.00+41.18%

  • Strong buy 1
  • Buy 0
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $37.00High $55.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$0.72 vs $0.79
Surprise
-8.86%

Dividends

Dividend history
Annual dividend
$0.48
Last payment
$0.12
Ex-dividend date
Nov 25, 2026
Pay date
Dec 16, 2026

PAHC news

All PAHC news

Phibro Animal Health peers

Health Care sector
PAHC peer companies
CompanyPrice% ChgMarket capCompare
NBTXNanobiotix S.A. ADR26.50-2.98%$1.35Bvs PAHC
URGNUroGen Pharma Ltd.27.65-12.86%$1.36Bvs PAHC
QUREuniQure N.V.19.35-4.35%$1.36Bvs PAHC
NUVBNuvation Bio Inc. Class A3.80-0.26%$1.34Bvs PAHC
RAPPRapport Therapeutics Inc.23.16-1.82%$1.37Bvs PAHC
ANABAnaptysBio Inc.46.63-1.62%$1.39Bvs PAHC
TYRATyra Biosciences Inc.20.12+1.98%$1.39Bvs PAHC
INVAInnoviva Inc.18.410.00%$1.31Bvs PAHC

Indexes, lists and sector

Phibro Animal Health stock FAQ

What is Phibro Animal Health's stock price today?

PAHC last traded at $33.29 as of Nov 20, 4:00 PM EST, down 2.32% on the day. Prices are delayed at least 15 minutes.

Does Phibro Animal Health pay a dividend?

Yes. Phibro Animal Health pays $0.48 per share annually, a 1.44% yield. The most recent dividend of $0.12 had an ex-dividend date of Nov 25, 2026.

What is PAHC's P/E ratio?

PAHC trades at a trailing P/E ratio of 13.26 and a forward P/E of 8.58.

Who is Phibro Animal Health's CEO?

Mr. Daniel M. Bendheim J.D. is the chief executive officer of Phibro Animal Health Corporation Class A, which has about 2,605 employees.

What is the PAHC 52-week high?

The 52-week high for PAHC is $60.08 and the 52-week low is $28.25. The stock is currently 44.6% below its high.

Compare PAHC